Vanda Pharmaceuticals Reports Fourth Quarter 2018 and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Vanda Pharmaceuticals (VNDA) PT Lowered to $21 at Oppenheimer
February 14, 2019 8:10 AM ESTOppenheimer analyst Esther Rajavelu lowered the price target on Vanda Pharmaceuticals (NASDAQ: VNDA) to $21.00 (from $29.00) while maintaining a Perform rating.
The analyst commented, "VNDA reported 4Q results that were higher than our estimates and provided 2019 guidance which came in below our (and... More
